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Abstract
Triple negative breast cancers (TNBC) are difficult to treat due to a lack of targets and heterogeneity. Inhibition of
angiogenesis is a promising therapeutic strategy, but has had limited effectiveness so far in breast cancer. To quantify
heterogeneity in angiogenesis-related gene expression in breast cancer, we focused on two families – VEGFs and
semaphorins – that compete for neuropilin co-receptors on endothelial cells. We compiled microarray data for over 2,600
patient tumor samples and analyzed the expression of VEGF- and semaphorin-related ligands and receptors. We used
principal component analysis to identify patterns of gene expression, and clustering to group samples according to these
patterns. We used available survival data to determine whether these clusters had prognostic as well as therapeutic
relevance. TNBC was highly associated with dysregulation of VEGF- and semaphorin-related genes; in particular, it appeared
that expression of both VEGF and semaphorin genes were altered in a pro-angiogenesis direction. A pattern of high VEGFA
expression with low expression of secreted semaphorins was associated with 60% of triple-negative breast tumors. While all
TNBC groups demonstrated poor prognosis, this signature also correlated with lower 5-year survival rates in non-TNBC
samples. A second TNBC pattern, including high VEGFC expression, was also identified. These pro-angiogenesis signatures
may identify cancers that are more susceptible to VEGF inhibition.
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Introduction
Angiogenesis is the formation of new blood vessels from existing
networks of capillaries. This blood vessel sprouting and remodel-
ing, which is a normal part of organ growth and of adult
physiology, can be co-opted to supply tumors by stimulating the
growth of new branches from the host organ vasculature.
The vascular endothelial growth factor (VEGF) family (Figure 1)
plays a large role in the regulation of angiogenesis. This family
comprises five ligands (VEGFA, VEGFB, VEGFC, VEGFD, and
PlGF) and three receptors (VEGFR1, VEGFR2, and VEGFR3).
There are also two neuropilin co-receptors (NRP1 and NRP2).
VEGFR2 signaling plays a prominent role in promoting angio-
genesis, while VEGFR3 signaling promotes lymphangiogenesis
[1,2,3].
Inhibition of angiogenesis, depriving tumors of nutrients by
preventing the formation of a surrounding vasculature, has shown
promise as a therapy for cancer. The VEGF-neutralizing antibody
bevacizumab is currently approved for treatment of colorectal,
lung, brain, and kidney cancers [4,5,6,7]. Tyrosine kinase
inhibitors such as sunitinib and sorafenib, which inhibit the kinase
activity of VEGF receptors, are approved for use in kidney,
pancreatic, stomach, and liver cancers [8,9,10,11]. Angiogenesis
inhibition has also been shown to have an effect on progression-
free survival in breast cancer, but a lack of effect on overall survival
has limited its use for this disease [12,13]. Accelerated approval for
bevacizumab in breast cancer was withdrawn in 2011 after 3
years. The limited effectiveness of these therapies – in particular
the variability in efficacy between cancer types and even between
individuals – necessitates a better understanding of the mecha-
nisms through which VEGF signaling inhibitors act, and the
environment in which they find themselves.
Varying responses to treatments among populations of breast
cancer patients reflects the fact that breast cancer is a heteroge-
neous disease. Breast cancers are commonly divided into
subgroups based on the expression of three cell surface receptors:
estrogen receptor (ER), progesterone receptor (PR), and HER2.
Tumors that are negative for all three of these receptors (‘‘triple-
negative’’) tend to have poorer prognoses due to a more invasive
phenotype and fewer treatment options [14]. A second, somewhat
orthogonal classification defines breast tumors as basal or luminal;
the major difference being which types of keratins are expressed,
as determined by immunohistochemistry. A third classification
uses gene expression signatures to group breast cancers into five
intrinsic subtypes based on a subset of 50 genes (‘‘PAM50’’): a
basal group and two luminal groups (luminal A and B), as well as
normal-like and HER2-enriched groups. Luminal groups tend to
be ER-positive while basal tends to be ER-negative [15].
Substantial overlap exists between triple negative breast cancers
(TNBCs) and basal tumors [16]: a large proportion of TNBCs are
basal, whereas a smaller proportion of non-TNBCs are basal [17].
TNBCs can be further subdivided into multiple different subtypes
[18]. Angiogenesis inhibition is of particular interest in TNBCs, as
the VEGF concentration and microvessel density are often higher
in these tumors than in non-TNBC tumors [19,20].
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The effectiveness of therapies that target VEGF signaling may
be modified by the presence of other ligands that can bind to the
VEGF co-receptors neuropilin-1 and neuropilin-2. One such
family of neuropilin-binding proteins are the class 3 semaphorins,
which have been shown to have inhibitory effects on tumor
progression and angiogenesis, possibly through competition with
VEGF for binding to neuropilins [21,22,23,24,25,26]. While class
3 semaphorins require neuropilins for binding and signaling
though plexin receptors, other semaphorins (classes 4, 5, 6, and 7)
bind to plexins directly [22]. Despite the lack of neuropilin binding
by these semaphorins, they have been shown to affect VEGF
signaling as well, either through direct interactions with VEGF
receptors [27] or through modulation of downstream signaling
pathways [28,29]. These indirect VEGF-semaphorin interactions
suggest that: (1) semaphorins may be novel anti-angiogenic
therapeutic targets; and (2) semaphorins should be considered
when determining patient subgroups that may be responsive to
anti-VEGF therapies. Figure 1 shows a schematic of known
VEGF-VEGFR-semaphorin-plexin interactions (the genes and
their associated microarray probes are listed in Tables S2 and S3
in File S1).
In this study, we explore how gene expression of VEGF and
semaphorin ligands and receptors is altered in a large number of
breast tumors from many previously published microarray studies,
totaling over 2,600 individuals. Our analysis identifies differences
in VEGF and semaphorin ligand and receptor expression between
triple negative tumors and other tumors, as well as differences
among the subtypes of triple negative breast cancer.
Results
Expression Patterns Differentiating Normal and Tumor
Tissue
The 2,656 tumor samples were compared to 42 normal
samples to identify differentially expressed genes. Overall, 20 out
of 29 of the ligand probe sets differed between tumor and normal
tissues at a significance level of 0.01 (Figure 2A). All of the
VEGF ligands were up-regulated in tumors except PlGF. PlGF
had two probe sets on the U133A platform: one was down-
regulated and the other did not differ significantly between
normal and tumor tissues. Semaphorin ligand expression
differences varied, with a mix of up- and down-regulation.
Ligands in Figure 2A were annotated on the left axis with a color
of red if they were known to have pro-angiogenic functions, blue
for anti-angiogenic functions, gray if they had been shown to
both promote and inhibit angiogenesis in different studies, or
white if no data were available. The studies supporting these
designations are listed in Table S2 in File S1
[3,23,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44]. In
general, class-3 semaphorins inhibit angiogenesis, while the other
four classes have varying effects.
Although 20 out of the 26 receptor probe sets differed from
normal expression at a significance level of 0.01 (Figure 2B), the
overall magnitude of the fold change between tumor and normal
tissue was less for receptors than for ligands: the mean absolute
difference was 0.58 for ligands (mean of all points in Figure 2A)
compared to 0.32 for receptors (mean of all points in Figure 2B).
Most receptors that were differentially expressed were up-
regulated, with the exception of FLT4 (VEGFR3) and PLXNA1.
We used principal component analysis (PCA) to determine
patterns of covariation in gene expression between tumor and
normal samples. Projection of the gene expression data onto the
plane defined by principal components 1 and 4 (PC1, PC4)
showed the best separation between tumor and normal samples
(Figure 2C). Normal samples showed moderate values of PC1 and
high values of PC4; tumor samples had a broader range of PC1
values and lower values of PC4. High PC1 scores were associated
with high expression of VEGFC, KDR, NRP1, and PLXNC1,
and low expression of SEMA3A, SEMA7A, FLT1, and FLT4.
Low PC1 scores were associated with the opposite expression
pattern. Low PC4 scores were associated with a pro-angiogenesis
signature, a combination of high expression of VEGFA,
SEMA4D, NRP2, and PLXNA1, and low expression of several
secreted semaphorins: SEMA3B, SEMA3C, SEMA3E, SEMA3F,
Figure 1. Ligand-Receptor interactions for the VEGF and Semaphorin families. VEGF ligands bind to and signal through three RTKs:
VEGFR1, VEGFR2, and VEGFR3 (blue). Neuropilins are in red, with numbers to distinguish between neuropilin-1 and neuropilin-2. Semaphorin ligands
bind to and signal through Plexins A-D (green). Many (but not all) members of the VEGF and Sema3 families use Neuropilin 1 or 2 as a co-receptor for
binding to the canonical signaling receptors. This competition for Neuropilin is thought to represent one mechanism by which VEGF and Semaphorin
ligands antagonize each other; in addition, the downstream signaling of VEGFRs and Plexins can have opposite function. Note that not all splice
isoforms of VEGF-A, VEGF-B, and PlGF can bind to the receptors indicated, and that kinetic rates of binding vary among isoforms.
doi:10.1371/journal.pone.0061788.g001
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and SEMA3G. The advantage of the PCA-based approach for
comparing tumor and normal samples over the differential
expression analysis used in Figures 2A and 2B was that patterns
of co-expression could be observed. For example, KDR expression
by itself was not significantly altered between tumor and normal
samples (Figure 2B), but co-expression of KDR with VEGFC,
NRP1, and PLXNC1 was associated with tumors (Figure 2D).
VEGF and Semaphorin Gene Expression are Differentially
Regulated in Triple Negative Breast Cancer
To determine patterns in VEGF and semaphorin expression
that may be important in distinguishing various breast cancer
subgroups, we performed PCA on the expression measurements
for the 31 VEGF- and semaphorin-related genes in the data set
consisting of 2,656 tumors. We compared the scores obtained from
PCA with commonly used clinical variables and found that the
principal components had the most significant associations with
triple negative status (Figure S1C in File S1), as indicated by the
large logistic regression coefficients. Some significant associations
were found between the principal components and lymph node
status (Figure S1D in File S1) and tumor grade (Figure S1E in File
S1), but the coefficients were much smaller than those for triple
negative status. Tumor stage was not associated with the
components at all (Figure S1F in File S1). Additionally, we noted
that applying PCA to the VEGF-related gene subset alone failed to
distinguish TNBC samples from receptor-positive samples as
Figure 2. Differences in expression patterns of VEGF- and semaphorin-related genes between normal breast tissue (n=42) and
breast tumors (n=2,656). A–B, Differences in mean expression with 99% confidence intervals as determined by the Wilcoxon rank sum test for (A)
ligands and (B) receptors at the probe level. Ligands are marked with the following colors to denote known effect on angiogenesis: red for pro-
angiogenic, blue for anti-angiogenic, gray for context-dependent (could be pro-or anti-angiogenic) and white for unknown. Genes for which
expression is significantly altered in tumors are denoted by * (p,0.001) and the direction noted by an arrow. C–D, Principal component analysis
shows separation of tumors from normal samples based on first and second principal component scores (C), with corresponding gene expression
patterns given by the loadings for these components (D). Gene labels are only shown for genes whose loading vectors onto PC1 and PC4 exceed a
magnitude of 0.23. Circles denote the loading of genes whose names do not appear.
doi:10.1371/journal.pone.0061788.g002
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effectively as the combined data set (Figure S1A in File S1).
Applying PCA to the semaphorin-related gene subset alone
resulted in some significant associations with triple-negative status
(Figure S1B in File S1). The NRP1 and NRP2 genes were
included in both subsets. Together, this suggests that the (indirect)
interactions between the VEGFs and the semaphorins lead to
different neuropilin-regulated signaling activities in TNBC tumors
compared to receptor-positive tumors.
When applying PCA to the combined VEGF and semaphorin
data set, the projection of the data onto the fourth principal
component (PC4a, ‘‘a’’ to denote the all-tumor data set) provided
the highest degree of separation between TNBC samples and the
rest of the tumors (Figure 3A), with low values of PC4a
corresponding to TNBC samples. A group of tumors also scored
highly on PC3a. A relatively large proportion of these were TNBC
samples that did not score low on PC4a. PC1a had a slight
association with TNBC status but only in samples that scored low
on PC4a, while PC2a did not appear to have any association with
TNBC status. PC4a also was significantly associated with the basal
subtype (as defined by the PAM50 gene signature classifier
described previously [45]) (Figure S2 in File S1), consistent with
the similarities between TNBCs and the basal subtype.
Low PC4a scores were associated with a pro-angiogenic
signature consisting of high expression of VEGFA, SEMA4D,
NRP2, and PLXNA1 and low expression of SEMA3B, SEMA3C,
SEMA3E, SEMA3F, and SEMA3G. High PC3a scores were
associated with high expression of VEGFC, SEMA3A, SEMA3G,
SEMA5A, KDR, and FLT4, and low expression of VEGFA
(Figure 3B). Clustering based on just the PC3a and PC4a scores
resulted in two groups of tumors with higher amounts of TNBCs
(clusters 1 and 3, respectively, in Figure S3 in File S1). In addition
to the established roles of VEGFA and VEGFC as promoters of
angiogenesis, published experimental data has shown that other
genes associated with low PC4a and high PC3a, SEMA4D and
SEMA5A, also have pro-angiogenic function [29,39,40] (Table S2
in File S1). Interestingly, three of the ligands with reduced
expression in high PC3a and low PC4a samples, SEMA3B,
SEMA3F, and SEMA3G, had both anti-angiogenic and tumor
suppressor functions [23,30,31,36,37,38] (Table S2). The role of
SEMA3C in angiogenesis has not been well-defined, but like other
class-3 semaphorins, it binds to neuropilin receptors. Thus, it may
impair signaling by members of the VEGF family by competing
for neuropilin.
Examining the correlations between PC4a scores and all genes
whose expression was measured on the U133A platform revealed
that the ESR1 gene, which encodes ER, had the second highest
correlation with PC4a of all genes (Table S7 in File S1). Other
transcription factors associated with ER, such as GATA3 and
FOXA1, had high correlations as well. This indicated that the
association between PC4a score and TN status may arise primarily
because of an association with ER, as opposed to PR or HER2.
ER, PR, and HER2 did not appear in the list of the most
correlated genes with PC3a scores (Table S6 in File S1).
The MSL Subtype Differs Significantly from Other TNBC
Subtypes
Next we examined VEGF and semaphorin expression in TNBC
samples assigned to the TNBC subtypes discovered in Lehmann
et al [18]. PCA of VEGF and semaphorin expression for only the
TNBC samples revealed that of all of the subtypes, the
mesenchymal stem-like (MSL) subtype was most distinguishable
from the others (Figure 3C). The MSL subtype projected to low
values of the second principal component (PC2t, ‘‘t’’ to denote the
TNBC-only data set). The gene expression pattern corresponding
to low PC2t included low expression of VEGFA and high
expression of VEGFC, SEMA5A, and SEMA3G (Figure 3D). This
was similar to the PC3a from the analysis of all tumors in the
previous section (Figure 3B), except that the signs were reversed
(Figure S4 in File S1, also see Table 1 for a comparison of
expression signatures across all principal component analyses in
this study). There was substantial overlap between the triple
negative tumors that had high PC3a scores in Figure 3A and the
tumors that had low PC2t scores in Figure 3C, indicating that the
MSL subtype could likely be distinguished even in the PCA of all
of the tumors.
The median expression of VEGFA, VEGFC, SEMA5A, and
SEMA3G in the MSL subtype was closer to the median of
receptor-positive tumors than to that of TNBC samples. In the
case of VEGFA, SEMA5A, and SEMA3G, the expression levels in
the MSL subtype were closer to those of normal tissues than the
tumor average. On the other hand, VEGFC was expressed at
higher levels on average than in any of the other groups (Figure S7
in File S1), indicating that this subgroup may be susceptible to
angiogenesis inhibitors that target VEGFC instead of VEGFA.
Consensus Clustering Defines VEGF- and Semaphorin-
based Tumor Subtypes
We used consensus K-means clustering to determine VEGF-
and semaphorin-related subtypes independent of any other
classifications. This differed from the PCA-based clusters in
Figure 3 in that all gene expression variation was analyzed here
to determine the natural clusters that arise in VEGF- and
semaphorin-related gene expression. Consensus clustering re-
vealed 7 clusters (labeled A–G) for ‘‘all tumors’’ data (Figure S8 in
File S1), and 5 clusters (labeled J–N) for ‘‘TNBC-only’’ data
(Figure S9 in File S1). The gene expression for the seven tumor
clusters is illustrated in the heatmap in Figure 4, with the clusters
arranged by the number of TNBCs present in decreasing order.
High VEGFA-expressing clusters. The first two clusters (A
and B) in Figure 4 possessed the pro-angiogenic PC4a gene
expression signature noted in Figure 3, namely high VEGFA
expression and low expression of SEMA3B/3C/3F. Cluster A is
distinguished from cluster B by higher expression of FLT1
(VEGFR1), FLT4 (VEGFR3), and several semaphorins (including
SEMA3A), and lower expression of VEGFC, KDR (VEGFR2),
and NRP1. Both clusters have high percentages of TNBCs (78%
and 66%, respectively). Using the intrinsic classifier (PAM50,
Figure 4), these two clusters were found to contain most of the
basal subtype tumors. As expected, most of the TN tumors were
basal as well (rows 3 and 4 of Figure 4 compare the overlap
between the TN and basal subtypes). Both of these clusters had
low expression of the genes encoding for ER and PR (ESR1 and
PGR) and of some of their associated transcription factors
(GATA3, FOXA1, MYB), and high expression of proliferation-
related genes (the basal/luminal panel in Figure 4), consistent with
the basal subtype.
High VEGFR1/VEGFR3-expressing cluster. Cluster C in
Figure 4 had high expression of FLT1 (VEGFR1), FLT4
(VEGFR3), SEMA3A, and some other semaphorins, with low
expression of VEGFA, VEGFC, KDR (VEGFR2), NRP1,
SEMA3C, PLXNA1, and PLXND1. This cluster also had a
relatively high percentage of TNBCs (43%), but with a lower
amount of basal subtype tumors than the high VEGFA-expressing
clusters. This indicated that although many TNBCs had the pro-
angiogenic PC4a signature, it was not strictly required for a tumor
to be triple-negative. This cluster had low expression of the claudin
genes CLDN3, CLDN4, and CLDN7, raising the possibility that
tumors in this cluster were members of the claudin-low subtype, a
VEGF and Sema Expression Define TNBC
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group of breast tumors known for their invasive, mesenchymal-like
behavior.
High VEGFC-expressing cluster. Cluster D in Figure 4 had
high expression of a group of genes including VEGFC, KDR
(VEGFR2), NRP1, and SEMA5A. This corresponded to the
alternative pro-angiogenic TNBC PC2t signature noted in
Figure 3. This cluster had some TNBCs (16%). Significant overlap
was noted between this cluster and the luminal A subtype of the
PAM50 intrinsic classifier; 67% of cluster D tumors were luminal
A, representing 30% of all luminal A tumors. Cluster D was
notable in that it had the highest expression of transcription factors
implicated in the epithelial-to-mesenchymal transition (EMT),
including SNAI2, TWIST1, ZEB1, and ZEB2 (the panel labeled
‘‘EMT’’ in Figure 4). This could indicate a role for VEGFC-
mediated signaling in tumors undergoing an EMT.
High SEMA3-expressing clusters. Clusters F and G in
Figure 4 had the anti-angiogenic high PC4a signature described
previously: high expression of the anti-angiogenic semaphorins
SEMA3B, SEMA3E, and SEMA3F, with low expression of
VEGFA. These clusters had the lowest number of TNBCs and
were mostly luminal A or B when classified into the PAM50
intrinsic subtypes. The pattern of expression of luminal markers
and proliferation-related genes was opposite to that noted for the
high VEGFA-expressing clusters: expression of ESR1, PGR, and
associated transcription factors was high while expression of
proliferation-related genes was low.
Consensus Clustering Defines VEGF- and Semaphorin-
based TNBC Subtypes
The 5 TNBC clusters, denoted J–N (Figure 5), were ordered as
closely as possible to the tumor clusters in Figure 4. Thus the
Figure 3. Triple negative breast cancers and the mesenchymal stem-like (MSL) subtype of triple negative breast cancers are
associated with increased pro-angiogenic gene expression and decreased anti-angiogenic gene expression. A–B, Principal
component analysis (PCA) scores (A) and loadings (B) for VEGF- and semaphorin-related genes in all tumors. Gene names are only shown for probes
whose loadings on the two principal components exceeded a radius of 0.2 from the origin. Circles denote genes whose names do not appear. Triple-
negative (TN) samples project to lower values of tumor PC4a, corresponding to high VEGFA and low SEMA3 expression. C–D, PCA scores (C) and
loadings (D) for VEGF- and semaphorin-related genes in only the TN samples. The MSL subtype projected to low values of TNBC PC2t, corresponding
to up-regulation of VEGFC, SEMA3G, and SEMA5A and down-regulation of VEGFA.
doi:10.1371/journal.pone.0061788.g003
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majority of samples in cluster A of Figure 4 fall into cluster J of
Figure 5, and so on. The relationship is not perfect; many samples
are differentially classified between the two cluster analyses.
The 5 TNBC clusters had similar expression patterns to the
clusters described above for all tumors. TNBC clusters J and K
had higher VEGFA expression on average, and as with clusters A
and B, were differentiated by the pattern of high FLT1, FLT4,
SEMA3A in cluster J and high KDR, NRP1 in cluster K. Clusters
L and M had lower VEGFA expression, with cluster L expressing
high levels of PGF, FLT1, FLT4, and SEMA3A, and cluster M
Figure 4. Heatmap of the 7 VEGF/Sema-based tumor clusters. Samples are ordered across the columns by cluster membership as determined
by consensus K-means clustering. The clusters are ordered by TN content, with cluster A on the left having the highest percentage of TNBCs. The
VEGF/Sema-based clusters are able to differentiate the basal intrinsic subtype from the other intrinsic (PAM50) subtypes. As previously noted, the
basal subtype is strongly associated with triple negative tumors (third and fourth bars: black for basal TNBCs and non-basal TNBCs, respectively).
Other breast cancer-related genes have expression patterns that align with the VEGF/Sema-based clusters.
doi:10.1371/journal.pone.0061788.g004
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expressing high levels of VEGFC, KDR, and NRP1. Cluster D
had low PC2t scores from Figure 3C/D. The fifth cluster was not
particularly distinguishable from the other TNBC clusters.
Notably, all the clusters except cluster M were heavily populated
by tumors of the basal PAM50 intrinsic subtype. This was seen for
clusters A and B in the all-tumor data set (Figure 4), but not for
clusters C and E. This is further evidence for the association
between the basal subtype and TNBC; basal tumors comprised a
small minority of clusters C and E in Figure 4, but this minority
became the majority in Figure 5 when only the TN tumors were
considered.
The TNBC subtypes found in Lehmann et al [18] had some
associations with the VEGF2/Sema-based clusters found here. Of
tumors in the MSL subtype, 81% were found in cluster M,
Figure 5. Heatmap of the 5 VEGF/Sema-based TNBC clusters. Consensus K-means clusters of only the TNBC data are arranged according to
the ordering from Figure 4, in that the TNBCs that appeared in tumor cluster A generally now appear in TNBC cluster J (although the correspondence
is not perfect) and so on for the other clusters. The VEGF/Sema-based clusters are able to differentiate the MSL subtype from Lehmann et al. (cluster
M) from the other TNBC subtypes. Claudin-low subtype-related patterns of gene expression in the panel labeled ‘‘EMT’’ were associated with cluster
M, the MSL-enriched cluster.
doi:10.1371/journal.pone.0061788.g005
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comprising 65% of the tumors in that cluster. This corresponds to
the PCA results that demonstrated a strong association of PC2t
with the MSL subtype. Most of the other subtypes were evenly
distributed across the clusters, with the exception of the basal-like 1
(BL1) subtype, which comprised 66% of cluster J.
Patterns of expression for other genes when sorted in the order
of the TNBC clusters were less apparent in Figure 5 than in
Figure 4, with cluster M showing the most significant regulation.
Growth-associated genes such as FOXM1, AURKB, and MKI67
were strongly down-regulated in this cluster while the EMT-
associated transcription factors SNAI2, TWIST1, ZEB1, and
ZEB2 were up-regulated. Notably, the claudin genes CLDN3,
CLDN4, and CLDN7 were down-regulated the most in this
cluster, consistent with the observation that the MSL subtype and
claudin-low subtype are closely related [19].
Validation Using TCGA Data
Using two TCGA data sets consisting of 537 tumors quantified
using a different microarray platform (Figures 6A and 6B) and 750
tumors quantified using an RNA-Seq platform (Figures 6C and
6D), we showed that the same patterns of gene expression that
distinguish TNBCs from other tumors could be found in other
patients using different technologies. PCA scores between the two
platforms used in the TCGA datasets had strong correlations
(Figure S5 in File S1). Patterns of gene expression associated with
the 2,656-tumor dataset were found in both TCGA datasets
(Figure S6 in File S1), including the low PC4a gene expression
signature of high VEGFA and low SEMA3B, SEMA3C,
SEMA3F, and PLXNB1. Some additional genes were altered
consistently in the two validation data sets as well: SEMA5B,
SEMA7A, and PLXNA1. All three of these had similar expression
patterns to that of VEGFA (Table 1 and Figure S10 in File S1).
Survival Analysis of Clusters
We performed Kaplan Meier survival analysis on the tumors to
determine the impact of the PCA-derived clusters on patient
prognosis. Triple negative status and increasing stage of the tumor
were both correlated with poorer prognoses as expected
(Figures 7A and 7B). Multivariate survival analysis using a Cox
proportional hazards model showed that tumor stage, lymph node
status, PC3a score, and PC4a score were all independent
prognostic factors (Table 2). Interestingly, triple negative status,
which was clearly correlated with poor survival, was not significant
in the multivariate model (p = 0.06). The likely reason for this is
that TN status is also highly correlated with PC4a scores. There
were more non-TNBC samples with low PC4a scores (n = 89) than
TNBC samples with high PC4a scores (n = 29), possibly resulting
in a stronger survival effect from PC4a score than from TN status
(Figure 7C). We also examined the interaction of ESR1 expression
with PC4a; both low ESR1 expression and low PC4a scores were
significantly associated with poor prognoses (Figure S12 in File
S1). Interestingly, PC4a score was significantly associated with
survival in a subgroup consisting of tumors with high ESR1
expression. Although ER+ tumors are already associated with
effective therapies, combination of existing therapies with angio-
genesis inhibition may provide additional benefits for these low
PC4a, ER+ tumors.
Survival analysis by cluster (Figure S11A in File S1) showed that
tumor clusters F and G had significantly better outcomes than the
rest of the clusters. These were the only clusters that had both low
PC3a scores and high PC4a scores (both anti-angiogenic
signatures), reinforcing the prognostic value of these two principal
components. The five TNBC clusters found here did not have
significantly different prognoses; instead the survival curves of the
clusters shared the same poor prognosis characteristic of TNBCs
(Figure S11B in File S1). Despite the lack of variability, the
differences in patterns of VEGF and semaphorin gene expression
may indicate different growth factor dependencies. For example,
VEGFC-targeting therapies may be more effective in cluster M,
while the rest may benefit more from VEGFA-targeting therapies.
Within each PAM50 subtype, ESR1 was not significant (Figure
S13 in File S1) while PC4a score was significantly associated with
survival only in the HER2-enriched subtype (Figure 7D). The lack
of association between survival and PC4a in the basal and luminal
PAM50 groups (Figure S13 in File S1) is not unexpected since
PC4a is somewhat consistent within these groups (low in basal,
high in luminal, as shown in the heatmap in Figure 4). The
prognostic effects of PC4a score in the HER2-enriched subtype
could indicate that a low-PC4a subgroup of patients treated with
HER2-targeting therapy may benefit from the addition of an anti-
angiogenic drug to their treatment. Overall the association of
survival and PC4a score in particular subtypes may aid in selecting
patients where anti-angiogenic therapy would provide the greatest
benefit.
Table 1. VEGF/Sema gene PCA loading patterns.
All Tumors (PC1a–4a) TNBC (PC1t–4t) TCGA-microarray (PC1m–4m) TCGA-RNA-Seq (PC1r–4r)
PC1 High VEGFC, KDR, NRP1 High FLT1, FLT4, SEMA3A, 6B, 7A High VEGFC, KDR, PGF, NRP1
Low FLT1, FLT4, SEMA3A, 7A Low KDR, NRP1 Low SEMA4F, 4G Low VEGFC, FLT1, KDR, FLT4, NRP1
PC2 High PLXNB1, PLXNB2 High VEGFA High VEGFA, PLXNA1 High SEMA3B, 3F, PLXNB1
Low SEMA4D Low VEGFC, KDR, NRP1,
SEMA3G, 5A
Low SEMA3B, 3C, 3F, PLXNB1
PC3 High VEGFC, KDR, FLT4,
SEMA3A, 5A
High PLXNB1, B2, B3 High VEGFA, PLXNA1, SEMA7A
Low SEMA4D, PLXNC1 Low PLXNA3, B3 Low SEMA3C
PC4 High SEMA3B, 3C, 3E, 3F High SEMA3F High SEMA5B, 6A, 6B High SEMA3A
Low VEGFA, SEMA4D, PLXNA1 Low VEGFB Low NRP2, PLXNC1, SEMA3A,
4D, 7A
Low VEGFA, PGF, FLT1, KDR, FLT4
The genes with the largest magnitude loadings are shown for each component across the 4 different principal component analyses performed in this study. All of the
expression patterns listed here correspond to samples with high scores for the particular component.
doi:10.1371/journal.pone.0061788.t001
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Discussion
Just as individuals have distinct genomic and gene expression
profiles, so too the tumors of each individual are distinct.
Understanding and quantifying this variability and individuality
is crucial for the development and targeting of therapeutics for
diseases as complex and heterogeneous as cancer. Triple negative
breast cancers (TNBCs), in particular, are a diverse and difficult-
to-treat set of tumors defined primarily by molecular targets for
treatment that they do not express, rather than targets that they do
express. Angiogenesis, a blood vessel morphogenesis process
underpinning the growth and metastasis of most tumors, is a
possible common target for TNBCs, and vascular endothelial
growth factor (VEGF) has been targeted in breast cancer as a key
regulator of angiogenesis. However, this has succeeded only for a
subset of breast cancer patients, and thus understanding which
subsets of patients may be responsive to this treatment is desirable.
This requires data from a large number of patients, and we used
one type of patient population data, gene expression microarrays,
to quantify changes in VEGF and semaphorin expression to define
relevant patient subgroups.
A high proportion of the genes considered here were
significantly different between normal breast tissue and breast
tumors (34/55 probe sets with p,0.001). This high rate of
significance may be an indicator that these genes are heavily
regulated by the genomic changes that occur in tumors.
Alternatively, the low number of normal samples (n = 42) relative
to tumor samples (n = 2,656) may result in an unrealistic estimate
for significance. It is important to note that the range/variability in
tumor expression is very high compared to the normal samples, as
indicated by the standard deviations of each group (Table S4 in
File S1). Although the mean values of expression for tumors and
normal tissues may differ, the range of tumor expression often
overlaps the range of normal expression. This makes individual
genes poor biomarkers; however, they can be combined to identify
tumor subgroups that correlate with differences in tumor
characteristics.
The overall expression changes were consistent with previously
reported breast cancer data of these genes at the mRNA and
protein level. The increased expression of VEGFA in TNBCs
compared to non-TNBCs was consistent with previous work that
found an approximately 3-fold increase of VEGF as measured by
ELISA of intra-tumoral samples from 679 patients [46]. VEGFR2
(KDR) was previously found to be significantly associated with
TNBC in a panel of tissue microarrays from 564 patients [46].
This is consistent with our results, which showed a relatively high
loading of KDR on the principal component associated with
VEGFC, NRP1, and PLXND1, which had the second highest
association with triple-negative (TN) status in the all-tumor data
set. The increased expression of VEGFC in TNBC samples found
here has also been demonstrated in IHC of breast cancer sections,
Figure 6. Validation of VEGF- and Semaphorin-related gene expression differences between triple negative and non-TN breast
cancers using TCGA data. A–B, Principal component analysis of TCGA microarray data set consisting of 537 breast tumors. C–D, Principal
component analysis of TCGA RNA-Seq data set consisting of 750 tumors. Both data sets were processed to gene-level measurements (rather than
probe-level) prior to downloading. Tumors were classified as triple negative based on gene expression data for the ESR1, PGR, and ERBB2 genes as
described in the Methods, all of which had clear bimodal distributions.
doi:10.1371/journal.pone.0061788.g006
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Figure 7. Angiogenesis gene expression subgroups correlate with survival. A–D, Survival curves for tumor samples that had available
survival data. A log-rank test was used to determine p-values. Triple negative (TN) status was associated with worse prognosis for 572 patients with
survival data (A). Higher tumor stage correlated with worse prognosis in 508 patients with available stage and survival data (B). Non-TNBC patients
with low PC4a scores had poor prognoses similar to the TNBC patients (C). Patients in the HER2-enriched PAM50 subtype had significantly poorer
prognoses if they also had low PC4a scores (D). E–F, Schematic of VEGF/semaphorin competition in the tumor microenvironment. The gene
expression patterns of the different subgroups of TNBC and other cancers suggest different regulation of pro- and anti-angiogenesis pathways. The
case with high expression of VEGFA and low SEMA3B, which corresponds to the high PC4a group, results in increased signaling through VEGF
receptors such as VEGFR2 (blue). Most TNBC fit this profile, although many non-TNBC did also and these showed decreased 5-year survival similar to
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where VEGFC stained positively in TNBCs significantly more
often than in non-TNBCs [47]. Studies examining the amount of
semaphorins and plexins expressed in breast cancer patients by
TNBC and non-TNBC subgroups are not available, but there are
some reports comparing their expression in normal breast and
tumor tissue. SEMA3A, SEMA3B, SEMA3F, PLXNA1, and
PLXNA3 were all shown by IHC to decrease as tumors
progressed, while NRP1 increased and NRP2 stayed the same
[48]. Another study showed the same pattern for PLXNA3
expression, while also showing that SEMA4F expression increased
as tumors progressed [49].
Using multiple clustering and analysis algorithms, we have
revealed patterns of gene expression associated with the triple-
negative subtype of breast cancer that may indicate a higher
collective pro-angiogenesis activity (Figure 4, tumor clusters A–C).
In addition to up-regulation of the well-known angiogenic growth
factor VEGFA in clusters A and B, several anti-angiogenic
semaphorins were down-regulated. SEMA3B and SEMA3F have
both anti-tumorigenic and anti-angiogenic properties
[23,30,31,36,37,50,51]. SEMA3C, whose role in angiogenesis is
less well-understood [32,33], was also consistently down-regulated
in tumors with high expression of VEGFA. Given that class-3
semaphorins compete with VEGF for binding to neuropilin co-
receptors, this overall pattern of gene expression may enhance
VEGF signaling in three ways: directly by increasing the amount
of VEGFA; indirectly by reducing the amount of competitive
inhibition for neuropilin; and decreasing anti-angiogenic Sema-
Plexin signaling. The survival analysis in Figure 7C demonstrates
the significance of this high-VEGF/low-Sema3 signature; patients
with this signature have similar poor prognoses regardless of their
triple negative status. The activity of angiogenesis in the TNBC-
enriched cluster C from Figure 4 is less clear: VEGFA is down-
regulated, while several semaphorins with both pro-angiogenic
(SEMA6B and SEMA7A) and anti-angiogenic (SEMA3A and
SEMA4A) effects are up-regulated.
What do these different gene-expression subgroups mean for
treatment? We would hypothesize that high-VEGFA-expressing
tumors would be more vulnerable to anti-VEGF treatment.
Clinical trial results for the anti-VEGF drug bevacizumab have
thus far not shown an increased efficacy in triple-negative subtypes
[12,52,53,54,55] (Table S5 in File S1); instead, similar improve-
ments have been seen in both triple negative and hormone
receptor positive cancers (all cases were HER2-negative). Howev-
er, we note that the high-VEGFA, low-Sema3 pattern (clusters A
and B in Figure 4) makes up only 69% of all TNBC samples, and
that 12% of non-TNBC samples can be classified as having a
similar gene expression profile, possibly confounding this analysis.
Other clusters found in the tumor data may be less susceptible
to inhibition of angiogenesis. The clusters with high expression of
class-3 semaphorins would likely not benefit from this type of
therapy because class-3 semaphorins function as endogenous
inhibitors of angiogenesis. These tumors would be expected to be
less aggressive; survival curves for patients with high class-3
semaphorin expression have the best prognoses (high PC4a in
Figure 7C). The gene expression pattern consisting of high
expression of VEGFC, PlGF, NRP1, and PLXND1 and low class-
3 semaphorin expression (PC3a in Figure 3A/B) is also likely to be
pro-angiogenic. However, it would not be expected to benefit from
an anti-VEGFA therapy; instead, a different target would be
needed to inhibit angiogenesis. This is supported by a report that
low IHC staining of VEGFC and NRP1 is associated with
improved progression-free survival in patients receiving bevacizu-
mab, while the level of VEGFA was not associated with changes in
progression-free survival [56].
The TNBC subtypes previously identified [18] demonstrated
similar expression of VEGF- and semaphorin-related genes with
the exception of the mesenchymal stem-like subtype. This subtype
was noted for its enrichment of genes involved with migration and
growth factor pathways, including KDR [18]. Here, we found a
cluster of angiogenesis-related genes with increased expression in
the MSL subtype, including VEGFC and KDR (TNBC cluster M
in Figure 5, corresponding to tumor cluster D in Figure 4).
Notably, however, VEGFA expression was decreased, indicating
that although angiogenesis may occur in tumors of this subtype,
VEGFA-targeted therapies are not likely to be successful
inhibitors. In the analysis of all tumors, this VEGFC-dominated
signature (tumor cluster D) was present in 18.5% of tumors. This
cluster had a low proportion of triple negative tumors, raising the
possibility that the MSL subtype may not just be a small subgroup
within TNBCs, but a therapeutically relevant subgroup of breast
cancers as a whole.
The concordance of the VEGF2/Sema-based clusters that we
found here with expression patterns of genes associated with the
basal/luminal distinction and EMT suggests that different breast
cancer subtypes utilize the VEGF and semaphorin signaling
pathways in consistently different ways. In particular, basal tumors
with high expression of growth-associated genes such as MKI67
and AURKB tend to have higher levels of VEGFA, presumably to
provide the rapidly proliferating cells with sufficient vasculature.
On the other hand, tumors with low expression of growth-
associated genes but high expression of EMT-associated tran-
scription factors such as SNAI2 and TWIST1 have low VEGFA
TNBC (C). Lower expression of VEGFA with high SEMA3B, corresponding to the low PC4a group, results in reduced signaling through VEGF receptors
and more signaling through semaphorin receptors such as PLXNA1 (green). Note that these schematics only consider receptor expression on
endothelial cells; signaling by plexins or VEGFRs on tumor cells may also play a significant role.
doi:10.1371/journal.pone.0061788.g007
Table 2. Survival analysis.
Univariate Multivariate
Parameter HR p-value HR p-value
TN 2.83 4.9*1027 1.72 0.06
Grade 3 vs. 1 or 2 1.57 0.03 0.87 0.55
Stage III vs. IIA or IIB 2.42 1.5*1025 1.58 0.05
Age .50 1.03 0.89 1.02 0.91
Lymph node positive
vs. negative
3.16 4.2*1025 2.17 0.02
PC1a.median PC1a 0.86 0.69 0.87 0.73
PC2a.median PC2a 0.69 0.08 0.91 0.66
PC3a.median PC3a 1.81 0.003 1.75 0.01
PC4a.median PC4a 0.364 7.3*1026 0.52 0.02
PC5a.median PC5a 1.22 0.33 1.21 0.36
PC6a.median PC6a 1.61 0.02 1.30 0.21
A Cox proportional hazard model demonstrated that the third and fourth
principal components had significant effects on survival of patients, even when
accounting for clinical variables.
doi:10.1371/journal.pone.0061788.t002
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expression and high VEGFC expression. The lymphangiogenic
VEGFC may facilitate invasion by allowing tumor cells to travel
through the lymphatics, a commonly used route of metastasis in
breast cancer [47]. This highlights the usefulness of this study not
just in targeting anti-angiogenic therapies, but in understanding
tumor biology as well.
One limitation of using gene expression microarrays on tumor
samples taken from biopsies or surgeries is that the samples are
heterogeneous. Along with the tumor cells they also contain
stromal cells, including endothelial cells, fibroblasts, and immune
cells. The expression of most of the ligands considered here can be
assumed to be predominantly attributable to expression in the
tumor cells, but for receptor expression the analysis is less
straightforward. This is particularly true for receptors whose
primary function of interest is on a cell type making up a small
percentage of the total, e.g. endothelial cells. Their expression may
be up-regulated in those cells but down-regulated in the more
numerous cell type, resulting in detection of no or opposite change
in expression in the microarray measurement of the heterogeneous
sample. Immunohistochemistry can address this issue by measur-
ing the cell-type-specific protein expression. For example, studies
in a wide range of breast tumors have shown that NRP1 and
NRP2 are both expressed on almost all endothelial cells, but very
rarely on breast tumor cells [57,58]. Conversely, PLXNB1 has
been shown to be expressed on the surface of tumor cells, but less
so on neighboring endothelial cells [59]. Thus, differences in
expression of NRP1 and NRP2 measured by microarray can be
assumed to be primarily due to endothelial cells, and differences in
PLXNB1 due to tumor cells. Laser capture microdissection or
other sorting methods could also resolve cell type differences by
isolating specific cell types prior to analyzing gene expression.
Methods such as these will be particularly useful in determining
the relative amount of VEGF signaling taking place in tumor and
endothelial cells.
We have yet to determine whether the VEGF- and Sema-
phorin-based clusters found here are recapitulated in gene
expression data for breast cancer cell lines. Extensive work has
been done to characterize the subtypes found in these cell lines and
the differential susceptibility of the cell lines to various therapeutics
[60,61]. Many aspects of VEGF and semaphorin signaling depend
on other cells in the tumor microenvironment, in particular
endothelial cells and tumor stromal cells, and an analysis of cell
lines could aid in determining which differentially expressed
ligands in the present study arise due to tumor cells and which are
due to stromal cells; as well as insight into whether observed
receptor expression variation is due to tumor cells or tumor-
associated endothelial cells.
We analyzed survival data in part to assess whether the VEGF-
and Semaphorin-based clusters were associated with prognosis of
breast cancer patients. The high correlation of VEGF- and
Semaphorin-related gene expression with existing prognostic
indicators such as TN status confounds the analysis and makes it
impossible to determine from this data why some patients have
poorer prognoses. However, we used a multivariate Cox
proportional hazards model and Kaplan-Meier plots to demon-
strate that a subgroup of ER+ tumors with the pro-angiogenic
PC4a signature had poorer prognosis. Thus, the pro-angiogenic
PC4a signature may have a role in severity of the disease,
independent of ER or TN status. To determine the actual
significance of the VEGF- and Semaphorin-based groups found
here, experimental models of breast tumors are needed. Tumor
xenografts in immunocompromised mice could be used to
measure the growth and invasion of tumors of the various
subtypes. This type of experimental model provides the advantage
of allowing for other processes that contribute to cancer
progression other than tumor cell growth, including angiogenesis.
Targeted VEGF inhibitors and inhibitors of VEGF-pathway
receptors could be administered to show whether the VEGF2/
Semaphorin-based signature found here is truly relevant in
tumorigenesis.
Computational models of VEGF and Semaphorin ligand-
receptor interactions will be useful in unraveling the effects of
the expression changes found here. The large number of proteins
involved, combined with the complexity of their interactions, will
make it necessary to use models to understand the overall effect of
the expression patterns on signaling through VEGF receptors.
Models of VEGF signaling [62,63,64] can be extended to include
the Semaphorins found to be relevant in the current study. These
models will enable prediction of patients expected to respond to
existing therapies and can suggest effective therapeutic targets.
Methods
Data Sets
Published human breast cancer gene expression data sets were
collated based on the following criteria: the tumors had to be
untreated, primary tumors, and the gene expression had to be
analyzed using the Affymetrix GeneChipH Human Genome
U133A platform. Of the 98 data sets returned by searching for
human breast tumors on the U133A platform in the GEO
database, 22 met the criteria of being untreated and primary as
of April 13, 2012. If available, the following data were also
collected: ER, PR, and HER2 immunohistochemistry (IHC),
lymph node status, age at diagnosis, tumor stage, and tumor
grade. The breast cancer data sets
[53,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83]
(Table S1 in File S1) were compiled into one expression data set
and normalized using the justRMA function in the affy Bioconductor
package of the R statistical software environment. Some samples
were removed prior to normalization: 30 samples in GSE20194
were replicates, 47 samples in GSE5847 were stromal cells
isolated by laser capture microdissection, and 20 samples in
GSE5847 had received neoadjuvant chemotherapy prior to
surgery when the sample was taken. Many of the samples in
different data sets were found to be from the same patients;
samples were removed so that each patient was represented in
the final data set only once. After removal of samples, the data
set consisted of 2,656 individual tumor samples and 42 normal
samples. When multiple probe sets corresponded to a single
gene, only the probe set with the highest variance across all
samples was used to represent expression of the gene.
The two TCGA data sets used for validation were current as of
April 25, 2012. One data set consisted of 537 tumor samples
analyzed on the Agilent G4502A microarray platform, while the
other was an RNA-Seq data set consisting of 750 tumor samples
analyzed on the Illumina HiSeq 2000 system. There were 481
patients overlapping between these two TCGA data sets. This
replication was allowed in order to show similar results using
different gene expression measurement technologies. Positive and
negative status for the receptors was assigned based on IHC if
available, otherwise based on the gene expression measurements
for the ESR1, PGR, and ERBB2 genes.
Assignment of TN Status and TN Subtypes
The assignment of triple negative status and subtype was made
based on the gene expression levels of ESR1, PGR, and ERBB2
when IHC data were not available, as previously described by
others [18]. A Gaussian distribution was fit based on expression of
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the three receptors for IHC TN samples, and another distribution
was fit for IHC receptor-positive samples. Samples with no IHC
data were classified by computing the probability of being TN
based on the two density functions derived from samples with IHC
data. Comparison of IHC data to expression-based assignments
has demonstrated that misclassification of samples is rare (,3.6%)
[18].
Subtypes of the triple negative classification were assigned by
calculating subtype centroids based on the classification used
previously by others [15]: expression of ,2000 genes was used to
compute centroids of each of the six subtypes based on 193 tumor
samples. The classifier derived from this was tested using leave-
one-out cross validation and classified 171 of the 193 samples
correctly, for an accuracy of 88.6%. Testing the classifier trained
with all 193 samples resulted in correct classification of 187
samples, for an accuracy of 96.9%. This classifier was used to
determine the subtypes of the remaining 582 triple negative
samples.
PAM50 Intrinsic Subtypes
A previously used classifier for breast cancer involves the use of
50 genes to place tumors into one of five categories: basal, luminal
A, luminal B, HER2-like, and normal-like. The method for
classifying a new sample is to take the Spearman correlation
coefficient of the expression of the 50 genes in the sample with
each of the five class centroids. The class whose correlation
coefficient is the highest is the class to which the sample belongs,
unless all correlation coefficients are less than 0.1, in which case
the sample is unclassified [84]. It should be noted that no genes in
the PAM50 classifier overlap with the VEGF- and semaphorin-
related genes that we consider here; thus when we compare
VEGF- and semaphorin-based clusters, we are considering two
completely independent methods of classification.
Differential Expression
Genes for VEGF and semaphorin ligands and receptors that
were significantly different between two groups (e.g. tumor vs.
normal, receptor-positive vs. triple negative, etc.) were determined
by the Wilcoxon rank sum test. This was carried out using the
wilcox.test function in R.
Principal Component Analysis
Principal component analysis (PCA) was used to reduce the
dimensionality of the data sets from the 31 VEGF- and
semaphorin-related genes under consideration to a smaller
number of components that can reproduce most of the variability
in the data. The components are linear combinations of the
expression of the genes, and capture patterns of co-expression.
The prcomp function in R was used to perform PCA. The columns
of the x matrix returned by this function corresponded to the
scores, while the columns of the rotation matrix corresponded to the
gene loadings. For 2-D score plots where colors were used to show
different groups of samples, the statistical significance of differ-
ences in PCA scores between the groups was determined using
multivariate analysis of variance. The p-values were determined by
comparing the Wilk’s lambda statistic to a chi-squared distribu-
tion.
Logistic Rregression
For triple-negative status, lymph node status, tumor stage,
tumor grade, age at diagnosis, and tumor size, logistic regression
models were fit based on the scores of the first eight principal
components using the R function glm.
Survival Analysis
The R package survival was used to perform survival analysis on
tumor samples for which survival and clinical variables were
available. A log-rank test was used to assess univariate significance
of factors. A Cox proportional hazards model was used for
multivariate analysis of all factors.
Cluster Analysis
K-means clustering was performed on the 2656-sample data set
consisting of all of the breast tumors, as well as the 775-sample
data set consisting of all triple negative tumors. The R function
kmeans was used for clustering. To ensure that the algorithm
converged to the global minimum instead of a local minimum,
clustering was performed 50 times and the solution with the lowest
within-class sum of squares was used to determine the cluster
membership of each sample.
Consensus K-means clustering was used to assess the stability of
the clusters. This consisted of performing the clustering algorithm
100 times on different subsets of the data set, and then computing
the fraction of iterations in which any pair of samples were found
in the same cluster. At each iteration, the sample subsets were
determined by taking a random sample without replacement
whose size was 80% of the data set. The consensus matrix is a
visual representation of the fraction of iterations in which any pair
of samples co-clustered. The cumulative distribution of the
consensus matrix across all possible sample pairs was used to
determine the number of clusters. The appropriate number of
clusters was the cluster number at which no further increases in the
area under the cumulative distribution curve occurred. Typically,
the relative change in area is close to zero above a certain value of
K. For example, in the all-tumor data set and the TNBC-only data
set, values of K greater than and equal to 5 resulted in low relative
area changes (Figures S6B and S7B in File S1). To select the
appropriate number of clusters from these cases, the consensus
matrices were investigated to determine which cluster number
resulted in the most off-diagonal white space (Figures S6C-F and
S7C-F in File S1) [84].
Visualization of Data
Gene expression differences between tumor and normal samples
were plotted in Figure 2A and B as the log of the ratio of the two
means. Error bars corresponded to the 99% confidence interval of
the log ratio derived from the Wilcoxon rank sum test. The range
of gene expression across groups was shown in boxplots with the
extreme ends of the boxes corresponding to the 25th and 75th
percentile of the data and the line inside the box corresponding to
median. The whiskers extended to the furthest point outside of the
boxes that still fell within 1.5 times the interquartile range from the
nearest end of the box, where the interquartile range was the
difference between the 75th and 25th percentiles.
Heatmaps of gene expression data were generated in R using
the image function. Data were scaled (zero-mean, unit-variance)
and assigned colors, with red corresponding to high expression
and green corresponding to low expression. Ordering of genes in
the heatmaps was performed using the hclust function in R with the
complete-linkage agglomeration method. When dendrograms
were used, they were generated using the plot.dendrogram function
in R.
Supporting Information
File S1 Supporting information for this study. This file contains
Tables S1–S7, which list the datasets and genes analyzed in this
study, basic statistics on the gene expression measurements,
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clinical trial results with anti-angiogenic agents, and genes
correlated with PC3a and PC4a. It also contains Figures S1–
S13, which contain information on the relationship of principal
components to breast cancer subgroups, relationships between the
different principal component analyses performed on various
datasets, and additional details on K-means clustering; plus
heatmaps of the TCGA datasets and survival analyses of several
of the breast cancer subgroups considered in this study.
(PDF)
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